Contrave diet pill nears FDA approval

Orexigen Therapeutics (OREX), maker of the weightloss drug candidate Contrave, are awaiting FDA approval for the third newest diet pill likely to be approved. Contrave is the third prescription diet drug candidate to face the FDA’s advisory panel this year, and after Vivus’s (VVUS) Qnexa and Arena Pharmaceuticals’s (ARNA) Lorcaserin had their FDA decision delayed due to safety concerns. Currently… Read more →